Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: levomilnacipran Clear all
Completed Phase 4 Interventional Results available

Trial of Levomilnacipran in Geriatric Depression

NCT02466958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
levomilnacipran, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)

NCT01780389
View directory record Official record
Conditions
Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain
Interventions
Open-label flexibly dosed milnacipran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 4, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01331109
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 4, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

NCT01829243
View directory record Official record
Conditions
Fibromyalgia, Neurocognition
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

NCT01207453
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
24 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 1 Interventional

Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients

NCT01294059
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT01034462
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 4, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Results available

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

NCT01471379
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Spencer Dorn, MD, MPH
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran hydrochloride
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Savella in Treatment for Provoked Vestibulodynia

NCT01304589
View directory record Official record
Conditions
Vestibulodynia, Vulvodynia
Interventions
Milnacipran
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

NCT02288325
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

NCT02720198
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran, Quetiapine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Milnacipran
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Not applicable Interventional Results available

Novel Medication as a Potential Smoking Cessation Aid

NCT02265367
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Levomilnacipran, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 4, 2026, 7:39 PM EDT
Not listed Phase 4 Interventional

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

NCT01329406
View directory record Official record
Conditions
Osteoarthritis
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia

NCT00797797
View directory record Official record
Conditions
Fibromyalgia
Interventions
No Treatment Added, Milnacipran Added
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2011 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Fibromyalgia Treated With Milnacipran

NCT01125423
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Skin Biopsy
Drug · Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 4, 2026, 7:39 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Savella Pregnancy Registry

NCT01026077
View directory record Official record
Conditions
Fibromyalgia
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

NCT01337700
View directory record Official record
Conditions
Autism Spectrum Disorder, Asperger Syndrome, Aspergers Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 4, 2026, 7:39 PM EDT